• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Managed Care Approach to the Treatment of Neurogenic Orthostatic Hypotension

Publication
Article
Supplements and Featured PublicationsUnderstanding the Diagnosis, Management, and Treatment Options for Neurogenic Orthostatic Hypoten
Volume 21
Issue 13

Publishing Staff

Senior Vice President of Operations and Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Cindy Spielvogel

Project Director

Christina Doong

Proofreaders

Maggie ShawGriselda Demassey

Associate Editor

Jeanne Linke

Clinical Editor

Michael R. Page, PharmD, RPh

Designer

Julianne Costello

Associate Publisher

Justin Gallagher

Director of Sales

Sara Stewart

National Account Managers

Gabrielle ConsolaMichael Costella

Corporate Chairman and CEO

Mike Hennessy, Sr

Vice Chairman

Jack Lepping

Chief Operating Officer/CFO

Neil Glasser, CPA/CFE

President, Managed Markets

Brian Haug

Executive Vice President and General Manager

John Maglione

Human Resources Director

Shari Lundenberg

Chief Creative Officer

Jeff Brown

President of Pharmacy Times Office of Continuing Professional Education

David Heckard

Participating FacultyFaculty

Phillip A. Low, MD

Professor Department of Neurology

Mayo Clinic

Rochester, Minnesota

Stuart H. Isaacson, MD

Director Parkinson’s Disease and Movement Disorders Center of Boca Raton

Associate Professor of Neurology

Florida International University

Herbert Wertheim College of Medicine

Boca Raton, Florida

Editorial Support

Jill E. Allen, PharmD, BCPS

Drug Information Consultant

Pin Oak Associates

Salt Lake City, Utah

Faculty Disclosures

Phillip A. Low, MD, has no relevant commercial financial relationships or affiliations to disclose.

Stuart H. Isaacson, MD, has the following relevant commercial financial relationships or affiliations to disclose:

Grant/Research Support: Abbvie, Acadia, Acorda, Adamas, Addex, Amarantus, Auspex, Biotie, Cynapsus, Eisai, GE Healthcare, Ipsen, Kyowa, Lundbeck, Merz, Novartis, Neurocrine, Pfizer, Pharma2B, Roche, Santhera, Serono, Shire, Teva, UCB, US World Meds, Xenoport Consultant: Acadia, Acorda, Allergan, Amarantus, Auspex, Biotie, Britannia, Cynapsus, Eisai, GE Healthcare, Impax, Ipsen, Kyowa, Lundbeck, Teva, UCB, US World Meds, Xenoport Speaker’s Bureau: Abbvie, Acadia, Allergan, GE Healthcare, Impax, Lundbeck, Teva, UCB, US World Meds, Xenoport

Editorial Support Disclosures

Jill E. Allen, PharmD, BCPS, has no relevant commercial financial relationships or affiliations to disclose.

The American Journal of Managed CarePublishing Staff—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Cindy Spielvogel have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Office of Continuing Professional Education

Planning Staff—Dave Heckard; Maryjo Dixon, RPh; Donna Fausak; and Nathalie Harden have no relevant financial relationships with commercial interests to disclose.

© 2024 MJH Life Sciences
AJMC®
All rights reserved.